Article Text

Download PDFPDF
Atrial fibrillation: what do we know about screening and what do we not know about treatment?

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Both authors have contributed equally to this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SDP reports research grant support from Bristol-Myers Squibb, Pfizer, Janssen Pharmaceuticals, Boston Scientific, Gilead, and the Food and Drug Administration; Consultant/Advisory Board from Bristol-Myers Squibb, Pfizer, Janssen Pharmaceuticals, Boston Scientific, and Medtronic. RDL reports institutional research grant and consulting fees from Bristol-Myers Squibb; institutional research grant from GlaxoSmithKline; consulting fees from Bayer, Boehringer Ingelheim, Pfizer, Merck, Portola.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles